SELLAS LIFE SCIENCES GROUP I

Sellas Life Sciences stock fell 6.51% to $11.54, 24‑hour market cap $2.5B, with a 52‑week low of $1.39. Learn key data, recent performance, and industry context.

Sellas Life Sciences I surges as investors back its strong late‑stage oncology pipeline, solid capital strategy, and growing market confidence.

Sellas Life Sciences shifts from secured‑loan focus to a diversified pharma & diagnostic portfolio, boosting shares 14% in 24 hours while keeping long‑term strategy intact.